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Summary
The prospect of eff ectively treating cancer patients with immunotherapy is now becoming a clinical reality. This is a 
consequence of clinically relevant and successful results obtained by applying monoclonal antibodies against immune 
checkpoint inhibitor receptors and chimeric antigen receptor (CAR) T cell therapy to patients with otherwise lethal cancers. 
Despite this success, only a limited number of cancer types and a subset of cancer patients currently respond to these thera-
pies. Eff orts are now made to increase the number of cancer types and patients that can be treated successfully. This is an 
overview of the various approaches taken to this end.
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IMUNOTERAPIJA TUMORA: MEHANIZAM DJELOVANJA
Sažetak
Klinička imunoterapija onkoloških bolesnika je postala klinička realnost. To je posljedica klinički relevantnih i uspješ-
nih rezultata dobivenih primjenom monoklonskih protutijela protiv imunoloških kontrolnih molekula funkcije inhibitornih 
receptora te T-limfocita s kimeričnim antigenskim receptorima. Usprkos tim uspješnim i obećavajućim rezultatima, rezulta-
ti su postignuti samo protiv dijela tumora i opet u samo dijela bolesnika se postiže terapijski odgovor. U prikazanom radu 
dan je kratak pregled tih raznih imunoterapijskih pristupa.
KLJUČNE RIJEČI:  imunoterapija raka, inhibicija molekula kontrolnih točaka, tumorske vaksine, kimerični antigenski receptor (CAR), 
adoptivna stanična imunost.
INTRODUCTION
Until recently, standard cancer treatment of 
oncological patients comprised surgery, chemo-
therapy, hormonal therapy, targeted therapy and 
radiotherapy but not immunotherapy. Immuno-
therapeutic approaches were based on the as-
sumption that tumor cells can be antigenically dis-
tinct from normal cells and that the host’s immu-
nological system can recognize this antigenic 
diff erence and consequently should mount an an-
ti-tumor immune response against autologous tu-
mor cells. In clinical testing and applications these 
various immunological approaches were usually 
ineff ective or, when they were eff ective, which 
was rare, were not easily and broadly applicable 
and therefore not in routine use (1-8). Some of 
these tumor antigens which can be recognized on 
autologous tumor cells can be unique for particu-
lar tumor cells, i. e. tumor specifi c. They might be 
produced as a consequence of somatic gene muta-
tions in tumor cells in the course of their malig-
nant cell transformation or by new gene forma-
tions in the places of cromosomal translocations. 
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According to their generation process these anti-
gens are labeled neoantigens. In some cases over or 
aberrantly expressed normal molecules from non-
mutated genes on tumor cells can act as tumor 
 antigens. They then form the so-called group of 
tumor-associated antigens (TAAs). Examples of 
these is HER-2 molecule or cancer/testis antigens, 
respectively (9,10).
Immunological approaches and interven-
tions against tumors are conceptually diverse and 
technically-technologically of various degrees of 
complexity. These approaches are undergoing dy-
namic change because new scientifi c knowledge 
about the components of the immune system and 
how they function at the cellular and molecular 
levels is continuously accumulating. They aim to 
evoke by the autologous tumor cells or tumor an-
tigens in various forms the antigenic activation of 
the cells of the immune system, predominantly of 
the adaptive immunity, and to consequently 
achieve autologous tumor cell destruction. The 
advantage of such an evoked immune reaction is 
specifi city, a relatively low level of possible side-
eff ects and the formation of the immunological 
memory which enables a fast reactivation of the 
immune response in the case of reappearance of 
the same tumor cells or tumor antigens (1-8). Since 
these immunological approaches are diverse, 
there are also several possibilities for their classifi -
cation (11). One option is to position them in the 
patients’ disease course. Thus they can be posi-
tioned as adjuvant therapy, with preventive in-
tent, or as curative therapy in the case of patients 
with a metastatic disease. Another option is to di-
vide them with respect to active and passive im-
munity. In active immunity procedures the aim is 
to activate the patients’ immune system, in the 
past most frequently by using various vaccines. 
These vaccination approaches were based on the 
successful results obtained with experimental ani-
mals and their tumors. The majority of these ap-
proaches, sometimes technologically relatively 
simple, were usually therapeutically eff ective on 
experimental animals. When tried on cancer pa-
tients, they were, unfortunately, not eff ective. As a 
source of possible tumor antigens, killed autolo-
gous or alogeneic tumor cells were used or can be 
used (for example vaccine canvaxin) (12). Also fre-
quently used are synthesised tumor antigens usu-
ally in the form of peptides with various adjuvans 
and DNA molecules encoding tumor antigens. 
More recent vaccination approaches also include 
autologous dendritic cells which are professional 
antigen presenting cells. An approach frequently 
adopted in the case of these cells is to fi rst gener-
ate such cells in vitro from the patients’ peripheral 
blood cells, then to incubate or stimulate them 
with potential tumor antigens, and fi nally to rein-
fuse them back into the patients (for example vac-
cine sipuleucel-T) (13). Also, in tumor cells or den-
dritic cells various gene encoding potential tumor 
antigens or immunostimulatory cytokines can be 
inserted. More recent approaches use genetically 
modifi ed oncolytic viruses (for example talimo-
gene laherparepvec) (14) or humanized monoclo-
nal antibodies against cell surface regulatory mol-
ecules involved in regulatory feedback circuits 
(check-point molecules) (15,16). From the func-
tional point of view these regulatory molecules on 
lymphocytes can be conceived as either stimula-
tory or inhibitory receptors (1-8,11,15,16).
CHECKPOINT BLOCKADE
Antigenic activation of adaptive immunity 
cells (T- or B- lymphocytes) after antigen recogni-
tion through the antigen-specifi c receptor (the so-
called fi rst signal) includes, besides cytokine par-
ticipation, cell-cell regulatory interactions with 
cell membrane bound costimulatory or coinhibi-
tory molecules on other cells (the so-called secod 
signal). Through their antigen-specifi c receptor 
T-lymphocytes recognize antigens in the form of 
peptides as a molecular complex with the mole-
cules of the major histocompatibility complex on 
other cells. These other cells can be antigen-pre-
senting cells (such as dendritic cells) or target cells 
which, after their recognition, are going to be 
lysed by eff ector T-cells. Cell-cell interactions of 
the second signal are also molecular specifi c in 
terms of receptor-ligand interactions. In these in-
teractions the molecules present on lymphocytes 
function as receptors, while the ligand molecules 
are on other cells (antigen presenting or target 
cells). The net-eff ect of this second signal on anti-
gen stimulated lymphocytes can be their addition-
al activation or inhibition of the initiated activa-
tion. These inhibitory interactions or signals have 
a physiological regulatory function. They form a 
negative feedback mechanism that aims to pre-
vent a too strong immune activation or reactions, 
since this can cause, as a side eff ect, damage to the 
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body’s normal cells (autoimmune reactions). Be-
cause of this regulatory function, these membrane 
bound regulatory molecules are also called check-
point molecules and they in fact function on lym-
phocytes, as has already been mentioned, as stim-
ulatory or inhibitory receptors. The antibodies 
against inhibitory receptors can block these nega-
tive feedback signals with the net-eff ect of lym-
phocyte (re)activation. Examples of second-signal 
molecules include the stimulatory CD28 receptor 
molecule on T-lymphocytes and ligand molecules 
CD80 (B7-1) / CD86 (B7-2) on dendritic cells. Upon 
T-lymphocyte activation through these molecular 
interactions, what comes to be later physiologi-
cally expressed on these T-lymphocytes is the 
molecule CTLA-4 (cytotoxic T-lymphocyte anti-
gen 4; CD152), which is a molecular homolog of 
the molecule CD28. The function of this subse-
quently expressed molecule CTLA-4 is to initiate 
the negative feedback mechanisms and thus pre-
vent a too strong immune activation and reaction. 
The molecules CTLA-4 and CD28 are then in mu-
tual competition for the molecules B7, but the 
molecules CTLA-4 have a higher affi  nity than the 
molecules CD28 for interaction with the molecules 
B7. Consequently, what follows after the initial T-
lymphocyte activation is the physiological brak-
ing of their activation. It should be noted that there 
exist other molecules on T-lymphocytes and their 
ligands on other cells which also form second acti-
vatory signals and are currently being investigat-
ed. For example, the molecule OX40 (CD134) on 
T-lymphocytes and the ligand OX40L (CD252). 
The fi rst phase 3 clinical results in studies that 
used blocking monoclonal antibodies against in-
hibitory receptors on T-lymphocytes appeared in 
2010 and such studies continue to be performed. 
The fi rst successful results were obtained in pa-
tients with metastatic melanoma in which the hu-
manized monoclonal antibody ipilimumab 
against the inhibitory receptor molecule CTLA-4 
was used. Later results that were even more suc-
cessful and that pertained to several additional 
cancer types were obtained with the use of mono-
clonal antibodies against the inhibitory receptor 
PD-1 (programmed cell death protein 1; CD279) 
on T-lymphocytes or against the ligand molecule 
for this receptor on tumor cells (molecule PD-L1) 
(1-8,15-17).
Through this blockade of the negative feed-
back mechanisms, the activation of T-lymphocytes 
(anti-CTLA-4 blockade) or the reactivation of an-
ergized T-lymphocytes (anti-PD-1 or anti-PD-L1 
blockade) can be obtained, which in clinical set-
tings can result in tumor disease control, tumor 
regression and even a cure for patients suff ering 
from certain types of cancer (melanoma, non-
small cell lung cancer, renal cancer, Merkel cell 
carcinoma, urothelial carcinoma, head and neck 
carcinoma) (15-17).
PASSIVE IMMUNITY APPROACHES
Examples of immunotherapeutic approaches 
that are based on passive immunity involve injec-
tions of monoclonal antibodies against various 
molecules in cancer patients. Some target mole-
cules for these monoclonal antibodies can be cell 
membrane receptor molecules for growth factors 
(anti-EGFR, anti-HER2) where the applied mono-
clonal antibodies prevent or inhibit cancer cell 
stimulation. In cases where the applied monoclo-
nal antibodies are expected to evoke complement 
activation, facilitate tumor cell phagocytosis or ac-
tivate antibody-dependent cell-mediated cytotox-
icity (ADCC), some of these target molecules can 
be tumor antigens. Moreover, active cytotoxic 
drugs or isotopes can be linked to monoclonal an-
tibodies. Such conjugation with monoclonal anti-
bodies can lead to a higher specifi city of linked 
molecules against tumor cells and less side-eff ects. 
Examples include trastuzumab-emtansin and 131 
I-tositumomab combinations. Patients having 
metastatic melanoma or renal cell carcinoma can 
also be treated with immunostimulatory cyto-
kines, such as interferon-alpha (IFN-α) and inter-
leukin-2 (IL-2). Patients suff ering from metastatic 
melanoma have also the adoptive cell therapy 
(ACT) treatment option, which is a highly person-
alized cell cancer therapy involving the adminis-
tration to the cancer-bearing patient autologous 
immune cells with direct anticancer activity. These 
immune cells (T-lymphocytes) were previously 
isolated from the patients’ peripheral blood or 
their tumors, cultured in vitro, checked for reactiv-
ity, expanded in vitro, and reinfused back to the 
patients. In some patients with melanoma this ap-
proach can lead to a durable, complete regression. 
Owing to the technical complexity of this ap-
proach and the period of time required to obtain 
the required number of cytoxic T-cells in vitro, 
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which is a minimum of several weeks, this meth-
od is used in no more than a few institutions in the 
world. Currently also widely conducted are clini-
cal studies involving the use of similarly produced 
and in vitro grown T-lymphocytes with inserted 
genes as chimeric antigen receptors (CARs, Chi-
meric Antigen Receptors). These CARs lympho-
cytes are predominatly used in patients with he-
matological neoplasms and in which lymphocytes 
with CARs are directed against the CD19 mole-
cules (1,3,6,7,11,17-19).
CONCLUSION
In conclusion, it can be expected that as a re-
sult of the application of monoclonal antibodies 
that block molecular interaction in immunological 
negative feedback mechanisms and their relative-
ly simple applicability, immunotherapy (immu-
nooncology) will become a part of the standard 
everyday therapeutic arsenal in the treatment of 
oncological patients with certain tumor types. Un-
derway are intensive investigations into potential 
predictive parameters for the application of these 
monoclonal antibodies since not all patients with 
„responsive“ tumor types are going to benefi t. Ac-
count should also be taken of the possible side-ef-
fects of these monoclonal antibodies, which are 
usually autoimmune in nature. Medical personnel 
should have knowledge of the possible side-ef-
fects, their recognition and treatment. It can fur-
ther be expected that these monoclonal antibodies 
will be tested in combination with anti-tumor vac-
cines, which were not proven to be eff ective, in 
order to improve these vaccines’ chances of induc-
ing eff ective anti-tumor immunity (1,3,15-25).
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